CBR is the world's largest cord blood and cord tissue bank. Cord Blood is rich in Stem Cells that are unique to the newborn and family. Cryopreservation of the cells has been called a type of 'biological insurance' because the stem cells are then available for use in medical treatments involving cancers and blood and immune disorders. The stem cells are an exact match for the newborn and have a higher likelihood of use in siblings. Diseases treated include leukemia, lymphoma, aplastic anemia and more than 75 other conditions amenable to stem cell transplant. New directions with cord blood stem cells include regenerative medicine for cerebral palsy and hearing loss.
Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets, namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and it is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife has also established its presence in Myanmar, Vietnam, Macau, Brunei and Bangladesh.
Get contact details of over 700M profiles across 60M
companies – all with industry-leading accuracy. Sales and Recruiter users, try out our
Email Finder Extension.
Find business and personal emails and mobile phone numbers
with exclusive coverage across niche job titles, industries, and more
for unparalleled targeting. Also
available via our
Contact Data API.